Welcome to LookChem.com Sign In|Join Free
  • or
3-[(2R)-2-Amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione is a complex organic compound with a unique molecular structure. It is characterized by the presence of various functional groups, including amino, fluoro, methoxy, and trifluoromethyl groups, which contribute to its chemical properties and potential applications.

830346-50-4

Post Buying Request

830346-50-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

830346-50-4 Usage

Uses

Used in Pharmaceutical Industry:
3-[(2R)-2-Amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione is used as an intermediate in the synthesis of Elagolix-d6 Sodium Salt (E501016), a labelled analogue of Elagolix Sodium Salt (E501018). Elagolix Sodium Salt is a novel uracil phenylethylamine that acts as a potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonist, making it a potential candidate for the treatment of various hormonal disorders and conditions.
Used in Research and Development:
Due to its unique molecular structure and functional groups, 3-[(2R)-2-Amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione may also be used in research and development for the discovery and development of new drugs and pharmaceutical agents. Its potential applications in this field could include the investigation of its interactions with various biological targets, as well as its use as a building block for the synthesis of other complex organic compounds with potential therapeutic properties.

Check Digit Verification of cas no

The CAS Registry Mumber 830346-50-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,3,0,3,4 and 6 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 830346-50:
(8*8)+(7*3)+(6*0)+(5*3)+(4*4)+(3*6)+(2*5)+(1*0)=144
144 % 10 = 4
So 830346-50-4 is a valid CAS Registry Number.

830346-50-4SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-[(2R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione trifluoroacetate

1.2 Other means of identification

Product number -
Other names 3-[(2R)-2-Amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl-2,4(1H,3H)-pyrimidinedione

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:830346-50-4 SDS

830346-50-4Relevant academic research and scientific papers

AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS

-

, (2021/07/02)

The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3- methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts. The compound of formula (I) is represented by the following structural formula.

3-((R)-2-(AMINO-2-PHENYLETHYL)-1-(2-FLUORO-6-TRIFLUOROMETHYL BENZYL)-5-IODO-6-METHYL-1H-PYRIMIDINE-2,4-DIONE OR A SALT THEREOF, PROCESS FOR ITS PREPARATION, AND ITS USE IN THE SYNTHESIS OF ELAGOLIX

-

Page/Page column 30-36, (2021/05/07)

The present invention relates to a new intermediate useful in the synthesis of elagolix, to a process for obtaining said intermediate, to the use of said intermediate for preparing elagolix, and to a process for preparing elagolix making use of said inter

PROCESS FOR PREPARING ELAGOLIX SODIUM AND INTERMEDIATES THEREOF

-

Paragraph 0125; 0126, (2021/03/19)

The present invention provides improved processes for the preparation of elagolix and intermediates thereof. The intermediate of formula VII is achieved by a coupling reaction of a compound of formula V and a N-benzylidene protected compound of formula IV

AN IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM

-

, (2021/04/10)

An improved process for the preparation of Elagolix Sodium having the structural formula (I). The present invention relates to highly pure compound of formula (VI) as a solid which is useful in the preparation of Elagolix sodium. The present invention pro

3-[2(R)-AMINO-2-PHENYLETHYL]-5-(2-FLUORO-3-METHOXYPHENYL)-1-[2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL]-6-METHYL-1H-PYRIMIDINE-2,4(1H,3H)-DIONE HYDROCHLORIDE SALT (I) IN SOLID FORM, PROCESS FOR PREPARING SAME, AND USE THEREOF IN THE SYNTHESIS OF ELAGOLIX

-

Page/Page column 11-12, (2021/02/12)

The present invention relates to a new intermediate useful in the synthesis of elagolix, to a process for obtaining same, to the use of said intermediate for preparing elagolix, and to a process for preparing elagolix making use of said intermediate.

IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES

-

, (2020/12/11)

The present invention provides an improved process for the preparation of Elagolix sodium of formula (I) and its intermediates. The present invention also provides a compounds of formula (V) and (VI), (X), (Xa) and (Xb). The present invention further prov

GnRH receptor antagonist key intermediate and preparation method thereof

-

Paragraph 0042; 0047-0048; 0049; 0054-0055, (2020/10/21)

The invention belongs to the technical field of medicines, and particularly relates to a GnRH receptor antagonist key intermediate and a preparation method thereof. The preparation method includes thesteps of enabling a compound 2 and a chiral auxiliary (S)-tert-butylsulfinamide to be subjected to a condensation reaction under the action of a condensing agent to generate an imine compound 3; under the action of a reducing agent, reducing the imine compound 3 obtained in the step (1) to obtain a compound 4; performing acid hydrolysis on the compound 4 to obtain salt of a compound 1, and performing alkali treatment to obtain the compound 1. The chiral auxiliary is introduced to induce chirality, an existing chiral source method is overcome, and the method is easy to operate, mild in condition, good in yield, high in chemical purity and optical purity and suitable for industrial production.

PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM AND INTERMEDIATES THEREOF

-

Page/Page column 27; 30, (2020/10/17)

The present invention relates to compounds of Formula A, isomers, polymorphs and process of preparation thereof, wherein, S is a pharmaceutically acceptable salt, R is selected from hydrogen or C1-C3 alkyl group substituted with Rsu

Synthesis method of elagolix intermediate

-

, (2020/02/17)

The invention relates to a synthesis method of an elagolix intermediate. Specifically, the invention provides a synthesis method of an elagolix intermediate compound X and an elagolix intermediate compound I. According to the method, 2-fluoro-3-methoxy-phenylacetic acid is used as a raw material, and the steps of cyclization, hydrolysis, amino protection, condensation, Mitsunobu reaction and the like are carried out in sequence, so that the elagolix intermediate compound X and the elagolix intermediate compound I are obtained. The method has the advantages of cheap and easily available reagents, high conversion rate, simple operation and low process cost, and is suitable for industrialization.

Intermediate crystal form A of rotigotine and sodium salt thereof as well as preparation method and application thereof (by machine translation)

-

Paragraph 0023, (2020/10/04)

The invention discloses an intermediate crystal form A of and a sodium salt thereof, and a preparation method and application thereof, and relates to a medicine intermediate and a preparation method and application thereof. The preparation method provided

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 830346-50-4